Life Science Investing PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
Life Science Investing PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Life Science Investing PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine ), Aligned with FDA's CNPV National Priority Initiative
Life Science Investing PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine ), Aligned with FDA's CNPV National Priority Initiative
Life Science Investing PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine )
Life Science Investing PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine )
AEG Confirms Pre-Sale of 35% of Initial 8 MW UAE Capacity with Strong Revenue Outlook and Clear Expansion Path
AFDG - Embracing US strategy, acquisition of Butembo copper deposit in the DRC. Copper added to draft list of US strategic minerals
